AngioDynamics shares are finally showing signs of positive momentum. Click for this ANGO stock update and see if it is the ...

Q4 FY 2026. Management view "We capped off a year of consistent execution across the business with a strong fourth quarter. Full-year ...

Key Points Interested in AngioDynamics, Inc.? Here are five stocks we like better. Revenue growth was led by med tech: AngioDynamics reported Q4 revenue up 8% to $86.6 million and full-year ...

AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid third-quarter fiscal 2026 performance, ...

ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.

Endologix, a medtech that focuses on treatments for vascular diseases, expanded its offerings with the purchase of a mechanical thrombectomy system from Surmodics. The deal for the Pounce thrombectomy ...

"Our mechanical thrombectomy portfolio exhibited standout performance as commercial adoption continues to build with both AlphaVac and AngioVac, confirming our belief that we have the strongest ...

Researchers at King's College London have shown for the first time that AI can autonomously perform thrombectomy navigation in a physical lab setting, a step toward expanding access to life-saving ...

Landmark, lifesaving telerobotic mechanical thrombectomy to expand access to care for stroke, a leading cause of death and disability worldwide HOUSTON & PANAMA CITY, Panama--(BUSINESS WIRE)--XCath, a ...

Giving the clot-busting medication alteplase at the site of a blocked brain artery after blood clot removal may increase the number of patients who fully recover, according to preliminary ...